Lymphoma in China
For relapsed or refractory large B-cell lymphoma, China has four approved CD19 CAR-T products: axi-cel, relma-cel, ranicabtagene and inaticabtagene. Only axi-cel is also FDA-approved. Camrelizumab is China-approved for third-line classic Hodgkin lymphoma. Access is through hospital hematology departments or trials.
VerifiedLast verified
Treatments available
| Treatments | Status in China | Status in US | Sources |
|---|---|---|---|
| Axicabtagene ciloleucel (Yikaida / Yescarta), CD19 CAR-T | Approved in China | Approved in China | National Healthcare Security AdministrationElevar Therapeutics / GlobeNewswire |
| Relmacabtagene autoleucel (Carteyva), CD19 CAR-T | Approved in China | Not approved | PubMed CentralElevar Therapeutics / GlobeNewswire |
| Ranicabtagene autoleucel (HICARA), CD19 CAR-T | Approved in China | Not approved | JW TherapeuticsElevar Therapeutics / GlobeNewswire |
| Inaticabtagene autoleucel, CD19 CAR-T | Approved in China | Not approved | Elevar Therapeutics / GlobeNewswire |
| Camrelizumab (PD-1) for relapsed/refractory classic Hodgkin lymphoma, third line | Approved in China | Not approved | Shanghai Hengrun Dasheng (Harin Bio) |
Hospitals with documented programs
Informational listings from cited public sources, not recommendations.
ShanghaiRuijin Hospital, Shanghai Jiao Tong University School of Medicine上海交通大学医学院附属瑞金医院International deptVerified
ShanghaiFudan University Shanghai Cancer Center复旦大学附属肿瘤医院International deptReported
BeijingPeking University Cancer Hospital (Beijing Cancer Hospital)北京大学肿瘤医院No public intl deptVerified
GuangzhouSun Yat-sen University Cancer Center中山大学肿瘤防治中心International deptVerified
Hainan / Boao LechengRuijin Hainan Hospital, Shanghai Jiao Tong University School of Medicine (Boao Research Hospital)上海交通大学医学院附属瑞金医院海南医院（海南博鳌研究型医院）International deptReported
Clinical trials
585studies listed as recruiting with a site in China on ClinicalTrials.gov, as of 2026-10-26. See the list
We link trials only; enrollment decisions belong to trial teams. Since May 2026, charging patients to join clinical research is prohibited in China, as reported by AFP.
Frequently asked
How many CAR-T products treat lymphoma in China?
A June 2026 NHSA filing lists four marketed CAR-Ts for relapsed or refractory large B-cell lymphoma: axicabtagene, relmacabtagene, ranicabtagene and inaticabtagene. Relma-cel also covers follicular lymphoma.
[1] National Healthcare …[2] JW TherapeuticsAre lymphoma CAR-Ts covered by China's national insurance?
Not as of June 2026: the NHSA filing states none of the four was yet in the national basic medical insurance drug list. Foreign patients generally pay out of pocket.
[1] National Healthcare …Sources
- 2026 National Reimbursement Drug List application: ranicabtagene autoleucel (public version)
“In r/r large B-cell lymphoma, four CAR-T products are marketed in China (axicabtagene, relmacabtagene, ranicabtagene, inaticabtagene), none yet in the national basic medical insurance drug list.”
- A New Outcomes-Based Payment Plan From a Chinese Company to Improve Patient Affordability of CAR-T Product
“Lists Yikaida (axicabtagene ciloleucel) at about 1.166 million yuan per infusion and inaticabtagene at about 0.999 million yuan.”
- NMPA acceptance of sBLA for Carteyva as second-line treatment in r/r LBCL
“Carteyva has been approved by NMPA for three indications.”
- Harin Bio's CD19 CAR-T HICARA (Ranicabtagene Autoleucel Injection) Approved for Marketing
“On July 30, 2025, the National Medical Products Administration formally approved the New Drug Application for Ranicabtagene Autoleucel Injection (HICARA).”
- Elevar Therapeutics Receives FDA Complete Response Letter for rivoceranib plus camrelizumab in HCC
“Camrelizumab is currently approved for eight indications in China, including relapsed/refractory classic Hodgkin's lymphoma (third-line) and esophageal squamous cell carcinoma.”
- 16 CAR-T Therapies and Counting
“Seven therapies have been approved by the U.S. FDA.”
Information only. Not medical advice, diagnosis or a treatment recommendation. Talk to your doctor. In an emergency, call your local emergency number.